Esperion Therapeutics Presents Full Results of Phase 2 Clinical Trial Showing Its Novel Oral Therapy ETC-1002 Lowered LDL-C By Up to 43 Percent in Hypercholesterolemic Patients with Type 2 Diabetes by longitudeadmin | May 2, 2013 | Portfolio News
NxStage Announces FDA Clearance for New High Flow Capabilities with NxStage System One by longitudeadmin | Apr 30, 2013 | Portfolio News
Collegium Announces Results of Chronic Pain Patient Survey – Confirms Significant Unmet Medical Need for a Differentiated, Abuse-Deterrent, Extended-Release Opioid by longitudeadmin | Apr 30, 2013 | Portfolio News
An Independent Clinical Study Shows Association between ChemoFx® Results and Recurrence Free Survival in Cervical Cancer by longitudeadmin | Apr 30, 2013 | Portfolio News
Esperion Therapeutics Completes $33 Million Preferred Financing to Advance Its Novel Oral LDL-C Lowering Therapy to Later Stage Clinical Trials by longitudeadmin | Apr 26, 2013 | Portfolio News